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ABSTRACT
Hematopoietic stem cell chimerism can be established after low-dose conditioning regimens, although the risk
of donor cell rejection increases for unrelated donor transplantations. We added pretransplantation rabbit
antithymocyte globulin (6 mg/kg) to an established conditioning regimen of fludarabine (90 mg/m2) and
single-fraction total body irradiation (200 cGy) followed by postgrafting immunosuppression with cyclosporine
A and mycophenolate mofetil for 22 patients with hematologic malignancies. One patient rejected the graft and
successfully underwent transplantation with cells from a second donor by using the same conditioning
regimen. The actuarial probability of developing acute graft-versus-host disease grade II to IV before day 100
was 40%, although 9 of 14 patients who survived beyond 100 days developed chronic graft-versus-host disease.
These data support a hypothesis that the addition of antithymocyte globulin decreases the risk of graft-versus-
host and host-versus-graft reactions when combined with a nonmyeloablative conditioning regimen of flu-
darabine and total body irradiation.
© 2004 American Society for Blood and Marrow Transplantation
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mNTRODUCTION
High doses of systemic chemotherapy/radiother-
py were initially believed necessary to achieve hema-
opoietic chimerism in allogeneic hematopoietic stem
ell (HSC) transplantation. Dose-escalation studies
emonstrated that increases in the intensity of the
onditioning regimen led to lower incidences of en-
raftment failure but also to higher incidences of non-
ematologic toxicity. A variety of total body irradia-
ion (TBI)–based or busulfan-based regimens became
ccepted for conditioning of patients undergoing al-
ogeneic HSC transplantation, but the morbidity of
ose-intense conditioning limited transplantation to c
84ounger patients and those without comorbid ill-
esses.
The establishment of hematopoietic chimerism is
complex phenomenon affected by host immunocom-
etence, doses of hematopoietic and ancillary cells
nfused, and degree of histocompatibility between do-
or and recipient. Murine studies of syngeneic trans-
lantation demonstrated that low levels of durable
ngraftment could be achieved without any condition-
ng of the recipient [1]. A higher percentage of syn-
eneic donor chimerism could be achieved by using
arger cell inocula or administering low doses of che-
otherapy or radiotherapy, although similar low-dose
onditioning may not be adequate to establish HSC
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ATG in Nonmyeloablative Unrelated Donor Transplantation
Bhimerism in an allogeneic setting [2]. Studies of al-
ogeneic HSC transplantation in a canine model, how-
ver, demonstrated that increasing the intensity of the
osttransplantation immunosuppression regimen
ould offset a decrease in the intensity of the pretrans-
lantation conditioning regimen, thus allowing the
stablishment of donor cell chimerism without dose-
ntense conditioning of the recipient [3].
A variety of low-dose regimens have been devel-
ped by various transplant programs [4]. One of the
east intensive was based on the canine model that
emonstrated the ability to achieve at least mixed
himerism after a single 200-cGy fraction of TBI if
osttransplantation immunosuppression with high-
ose cyclosporine A (CSA) and mycophenolate
ofetil (MMF) was maintained [4]. In a pilot study in
umans undergoing related-donor peripheral blood
tem cell (PBSC) transplantation, however, a 20%
ailure of sustained engraftment occurred [5], and ﬂu-
arabine was added to this regimen. These investiga-
ors subsequently reported the treatment of 52 pa-
ients who received HSC from HLA-matched or
mismatched unrelated donors [6]. Durable donor
himerism was established for 88% of patients. The
ncidence of acute graft-versus-host disease (GVHD)
rade II to IV was 63%, and this was fatal for 9% of
he patients. However, day 100 transplant-related
ortality was only 11%, and 35% of patients re-
ained alive at a median follow-up of 19.3 months. A
ollow-up report limited to patients receiving HLA-
ompatible unrelated grafts described an overall inci-
ence of acute GVHD grade II to IV of 52%, but it
eported sustained engraftment for only 85% of PBSC
ecipients and only 56% of recipients of marrow [7].
he 1-year progression-free survival was 38%, and
ay 100 nonrelapse mortality was only 11%.
Other strategies to improve the proportion of pa-
ients with durable engraftment include infusing more
ells [8], an approach not easily achieved in unrelated
onor transplantation, or increasing the intensity of
he conditioning regimen, which would counter the
roposed beneﬁts of a low-dose conditioning regimen.
ntithymocyte globulin (ATG) is an immunosuppres-
ant that lacks the hematopoietic and nonhematopoi-
tic toxicities incurred with high-dose chemotherapy
r radiotherapy. Rabbit-derived ATG (rATG) is
uch more potent than that derived from equine
ources and has been shown to reduce the risk of
VHD in HSC transplantation [9,10].
We report a prospective study of unrelated donor
SC transplantation after ﬂudarabine and TBI con-
itioning with posttransplantation immunosuppres-
ion with CSA and MMF by using the regimen de-
cribed previously [6,7]. To achieve additional
mmunosuppression and address the higher risks of
raft rejection and acute GVHD observed for recipi-
nts of HSC from unrelated donors, we added rATG o
B&MTo the conditioning regimen. We report that the ad-
ition of rATG seems to decrease both the host-
ersus-graft and graft-versus-host reactions, thus lead-
ng to decreased risks of engraftment failure and acute
VHD.
ETHODS
atients and Donors
This was a prospective phase I/II study of unre-
ated donor transplantation that used a nonmyeloab-
ative conditioning regimen for patients with hemato-
ogic malignancies. The Institutional Review Board of
he Hackensack University Medical Center approved
his research study, and written, informed consent was
btained for all patients. Patients eligible for this study
ad a hematologic malignancy and were aged 50 years
r older, although younger patients deemed to be at
igh risk for transplant-related complications because
f comorbid conditions or prior dose-intensive ther-
pies were also eligible. No upper age limit was set.
HSCs (marrow stem cells or PBSC) for transplan-
ation were obtained through the National Marrow
onor Program or related registries. PBSCs from
lgrastim-treated donors were the preferred HSC
ource. HLA typing for patients and donors was by
olecular techniques with HLA-A and -B locus typ-
ng performed at a level equivalent to serologic tech-
iques. HLA-C, -DRB1, and -DQB1 loci were typed
y using high-resolution techniques. Conﬁrmatory
esting was performed for all patients and donors
efore ﬁnal selection of the donor. A 1-antigen mis-
atch was allowed at either class I or class II loci.
retransplantation Conditioning
Patients were conditioned for transplantation with
udarabine 30 mg/m2 intravenously (IV) daily on days
4, 3, and 2 and with rATG (Thymoglobulin;
angstat Medical Corp., Fremont, CA ) 3 mg/kg IV
aily on days 3 and 2 before transplantation. Dos-
ng of ﬂudarabine was based on actual weight. Dosing
f rATG was based on adjusted ideal body weight for
atients whose actual weight was greater than 120% of
deal body weight. TBI (200-cGy total dose given at
-9 cGy/min by using a linear accelerator without
ung shielding) was administered on day 0 before HSC
nfusion. The timing of this conditioning regimen was
ased on the intended day of infusion, deﬁned as day
, although the day at the completion of infusion for
SC products was deﬁned as the actual day 0 for
urposes of engraftment and other posttransplanta-
ion events.
VHD Prophylaxis, Staging, and Treatment
Posttransplantation immunosuppression consisted
f high-dose cyclosporin A (CSA; Neoral [Novartis
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7harmaceuticals Corp., New York, NY] or Gengraf
Abbott Laboratories Inc., Abbott Park, IL])
.25 mg/kg by mouth twice daily starting on day 3
nd MMF (Hoffmann-La Roche Inc., Nutley, NJ)
5 mg/kg by mouth twice daily rounded to the nearest
50-mg dose starting 6 hours after completion of the
raft infusion. CSA and MMF dosing were based on
djusted ideal body weight for patients whose actual
eight was greater than 120% of ideal body weight.
yclosporine levels were monitored twice weekly by
sing a monoclonal whole-blood ﬂuorescence polar-
zation immunoassay (TDx; Abbott Laboratories)
ith adjustments in dosage as needed to achieve a
arget level of 500 ng/mL and a range between 400
nd 600 ng/mL. MMF levels were not measured.
MF was tapered at 11% per week starting on day 40;
he taper was completed on day 96. CSA taper was
nitiated on day 100 at 8% per week, with completion
f the taper on day 177.
Patients were evaluated for the development of
VHD on a daily basis while hospitalized, weekly for
he ﬁrst 3 months after transplantation, and then at
-month intervals. The diagnosis of GVHD was based
n clinical criteria with histopathologic conﬁrmation
henever possible. Overall staging was based on pub-
ished criteria [11]. Patients who developed acute
VHD requiring treatment received prednisone 0.5
r 1 mg/kg twice daily for 10 days, followed by a taper
y 0.2 mg/kg/d every 5 days. MMF taper was initiated
r completed as described previously regardless of the
evelopment of acute GVHD. Patients who devel-
ped chronic GVHD were treated initially with pred-
isone with or without CSA [12].
upportive Care
The conditioning regimen, cell infusion, and ini-
iation of the GVHD regimen were performed in the
npatient setting for all patients, but patients resided at
ome after discharge from the inpatient unit. The
SC products were stored and transported at 4°C and
nfused without cryopreservation. No processing of
BSC products was performed. Depletion of red
lood cells or plasma from marrow products for man-
gement of red blood cell–incompatible recipient/do-
or pairs was performed in accordance with standard
ractices [13].
Patients were discharged to the outpatient setting
s soon as clinical status allowed. Peripheral blood cell
ounts, chemistry proﬁle, and cyclosporine levels were
btained twice weekly until at least 12 weeks after
ransplantation. Blood components (irradiated and
eukocyte depleted) were infused as needed to main-
ain hemoglobin levels more than 7.1 g/dL and plate-
et counts more than 10 000/L. Cytokines were not
dministered after transplantation. All patients re-
eived antibiotic prophylaxis consisting of oral acyclo- c
86ir 400 mg twice daily, penicillin 500 mg once daily,
nd trimethoprim/sulfamethoxazole 160/800 twice
aily 3 days per week (or dapsone 100 mg once daily
d/wk for sulfa-allergic patients) for 1 year after
ransplantation. Ciproﬂoxacin 500 mg twice daily was
rovided in place of penicillin for patients with an
bsolute neutrophil count 0.5  109/L. Broad-spec-
rum antibiotics were administered to patients who
xperienced fever during periods of neutropenia. Flu-
onazole 400 mg once daily was administered for
ungal prophylaxis through 7 weeks after transplanta-
ion. Blood samples were tested weekly for 12 weeks
fter transplantation for evidence of cytomegalovirus
CMV) reactivation by using a nucleic acid hybridiza-
ion test (Digene Hybrid Capture System; Digene
orp, Gaithersburg, MD). Patients with CMV reac-
ivation were treated with ganciclovir 5 mg/kg IV
wice daily for 14 days, followed by maintenance ther-
py of 5 mg/kg IV daily, 5 d/wk, until at least 3
onsecutive negative antigen tests were obtained.
valuation of Chimerism
Engraftment was deﬁned as the presence of 5%
eripheral blood CD3 cells of donor origin; com-
lete chimerism was deﬁned as 95% donor cells in
his cell population. Chimerism was determined by
uantitative polymerase chain reaction analysis of in-
ormative polymorphic variable number tandem re-
eat regions for sex-matched recipient/donor pairs or
y ﬂuorescent in situ hybridization analysis with
robes for the Y chromosome for sex-mismatched
airs. Whole-blood samples for analysis were obtained
t 4, 8, and 12 weeks after transplantation and again at
and 12 months after transplantation. These blood
amples were separated by ﬂow cytometry (Hemato-
ogics, Inc., Seattle, WA) into fractions enriched for
D3 cells and CD33 cells for testing. Bone marrow
amples were obtained at 8 and 12 weeks and again at
and 12 months for evaluation of disease and chimer-
sm; marrow samples were not fractionated before
himerism testing.
anagement of Progressive Disease or Relapse
fter Transplantation
Patients with evidence of progressive disease were
ble to undergo rapid withdrawal of immunosuppres-
ive medications if donor cell chimerism was estab-
ished. Infusion of peripheral blood mononuclear cells
donor lymphocyte infusion; DLI) was permissible for
atients with progressive disease but without active
VHD after withdrawal of all immunosuppressive
edications. The quantity of CD3 cells infused
ould be escalated at 6- to 8-week intervals at 3-fold
ncreasing doses starting at a dose of 1  106 CD3ells per kilogram of recipient weight.
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ATG in Nonmyeloablative Unrelated Donor Transplantation
Btatistical Analysis
This was a phase I/II study to determine the fea-
ibility of adding rATG to an established regimen of
udarabine and TBI. Patient characteristics and trans-
lantation outcomes are described with appropriate
ummary statistics such as median values and ranges.
he probabilities of censored events—such as the de-
elopment of acute or chronic GVHD or death after
ransplantation—were estimated by using the Kaplan-
eier procedure. These analyses were performed
ith SPSS version 12.0.1 software for Windows
SPSS Inc., Chicago, IL). Survival was determined as
he date of the last visit before December 31, 2003.
ESULTS
atient Enrollment
A total of 23 transplantations for 22 patients were
erformed, and patient and donor characteristics are
hown in Table 1. One patient (patient 1272) rejected
he ﬁrst graft and underwent a successful second
ransplantation 3 months later with the same condi-
ioning regimen but a different donor. Data for both
ransplantations are included in this analysis except for
ong-term chimerism testing for the ﬁrst donor after
he second transplantation. The median age of these
atients was 56 years (range, 24-72 years), and 16 were
ale. Seven patients previously underwent autologous
SC transplantation; 2 other patients received a prior
llogeneic transplant with a nonmyeloablative condi-
ioning regimen and cells from related (patient 1245)
r unrelated (patient 1272) donors. Five of the donors
ere female, and 4 of the male recipients received cells
rom a female donor. The CMV status of the patients
nd donors is shown in Table 1. Bone marrow prod-
cts were the source of cells for 8 of the transplants,
nd 16 of the transplants involved ABO-mismatched
roducts (5 major mismatches, 10 minor mismatches,
nd 1 bidirectional mismatch). HLA-disparate grafts
ere transplanted into 6 patients (Table 1). The me-
ian nucleated cell dose for the bone marrow products
as 2.9  108/kg (range, 1.8-4.8  108/kg), contain-
ng a median CD34 cell dose of 3.2  106/kg (range,
.8-6.5  106/kg) and a median CD3 cell dose of
.7  107/kg (range, 2.2-5.6  107/kg). As expected,
he median total nucleated cell, CD34 cell, and
D3 cell doses were higher for the PBSC recipients
t 12.3  108/kg (range, 6.2-23.2  108/kg), 6.1 
06/kg (range, 0.7-18.7  106/kg), and 2.6  108/kg
range, 2.1-5.0  108/kg), respectively.
ematologic Recovery and Donor Cell
ngraftment
Patients were followed up only twice weekly in the
utpatient setting, and the periods of neutropenia and
hrombocytopenia cannot be accurately determined. a
B&MTone marrow hypoplasia was common, although 7 of
3 patients maintained absolute neutrophil counts
0.5  109/L during the ﬁrst month after transplan-
ation, and 5 of 23 maintained platelet counts 20 
09/L without transfusion.
The primary engraftment end point of this study
as the development of sustained donor cell chimer-
sm. Two patients died from transplantation compli-
ations before chimerism testing could be performed.
nly 1 (patient 1272) of the other 20 patients did not
chieve this level of donor cell chimerism at any point
fter transplantation, and no patient experienced late
raft failure. In general, the percentage of peripheral
lood CD3 cells of donor origin increased with time
fter transplantation (Table 2), and no patient re-
uired DLI to improve donor cell engraftment. Pe-
ipheral blood myeloid cell (CD33) engraftment was
lso prompt, with a median of 98% (range, 0%-100%)
f donor origin at 28 days after transplantation. Chi-
erism studies on unseparated bone marrow samples
btained at 2 months after transplantation showed a
edian of 94% (range, 0%-100%) donor cells. As
xpected, the proportion of donor cells in these bone
arrow samples also reﬂected the presence of persis-
ent disease, with lower proportions of donor cells for
atients with relapsed or persistent disease at the time
f this testing.
onhematologic Transplantation Complications
The median time to initial discharge after trans-
lantation was 4 days (range, 1-52 days). The primary
eason for delay of discharge was nausea resulting
rom the posttransplantation immunosuppressive reg-
men. All but 1 patient required a subsequent hospital
dmission, and the median total number of days hos-
italized during the ﬁrst 100 days after transplantation
as 19 (range, 1-81); this includes hospitalization for
reatment of progressive disease for patients who ex-
erienced early disease relapse, as well as for treat-
ent of transplant-related complications.
Peritransplantation complications were frequent
or this patient population. Almost all patients com-
lained of rigors and became febrile during the ﬁrst
nfusion of rATG; symptoms during the second infu-
ion were less severe. Three patients (patients 1279,
397, and 1574) experienced hypotension that per-
isted for several hours after the ﬁrst rATG infusion
ut were able to receive the second infusion without
elay or complication. Although no patient developed
lopecia or mucositis as a result of the conditioning
egimen, complaints of persistent anorexia, nausea,
nd vomiting were common, especially for patients
ith higher CSA levels, until the MMF taper was
ommenced. Reversible increases in bilirubin level,
sually without increases in aspartate aminotransfer-
se or alkaline phosphatase, occurred presumably as a
787
Table 1. Patient and Donor Characteristics
Patient
No. Diagnosis/Stage
Prior
HSCT
Patient Donor
HLA (Mismatched Locus) HSC
Source
Cell Dose
Age
(y) Sex CMV ABO
Age
(y) Sex CMV ABO Patient Donor
TNC
(108/kg)
CD34
(108/kg)
CD3
(108/kg)
1192 Hod/Rel 3 Y 24 M Neg O 29 M Pos O — — BM 4.8 6.5 5.6
859 Myel/PD Y 51 M Pos A 30 M Neg B A 26 A 3 BM 3.0 ND ND
1279 Secondary
MDS/RA
Y 40 F Neg O 34 M Neg O C 0401 C 0403 BM 2.6 2.6 0.3
1272 Secondary
AML/CRI
N 64 M Pos A 21 F Neg A DQB1 0302 DQB1 0301 PBSC 13.8 6.3 3.2
1272 Secondary
AML/CRI
Y 65 M Pos A 52 M Pos O — — PBSC 9.5 3.9 2.5
818 Myel/PD Y 54 M Neg O 29 M Neg B — — PBSC 8.5 6.2 2.4
1159 CML/2nd CP Y 54 F Pos A 36 M Neg O — — PBSC 23.2 18.7 4.6
1356 AML/Rel 1 N 56 F Pos A 30 M Pos O — — BM 2.8 3.2 0.4
1378 CLL/stage IV N 55 M Pos A 40 M Neg O — — BM 4.6 4.0 0.4
1397 Secondary
AML/Rel 1
N 58 M Pos A 44 F Pos O — — PBSC 9.2 6.1 2.3
1406 MDS/RA N 65 M Pos A 27 M Pos O — — PBSC 12.9 15.2 4.1
1418 CLL/stage IV N 53 M Pos B 23 M Neg O — — PBSC 12.5 10.7 3.0
1455 Myel/PD Y 55 M Neg O 46 M Pos A DQB1 0502 DQB1 0301 PBSC 14.9 0.7 3.2
1245 MDS/RA Y 61 M Pos O 34 F Neg O — — PBSC 7.4 3.0 2.5
1476 MDS/RAEB N 72 M Neg O 29 F Neg A C 1203 C 0702 PBSC 8.5 4.6 2.1
1477 MDS/RA N 28 F Pos O 44 F Pos A — — BM 1.8 1.8 0.2
1508 NHL/Rel 1 N 61 M Neg B 30 M Neg O — — BM 2.4 2.3 0.3
1540 NHL/Rel 1 Y 54 M Neg A 36 M Neg A — — PBSC 6.2 6.1 ND
1562 CML/AP N 55 M Pos O 35 M Neg O — — PBSC 12.3 0.1 2.6
1582 Ph ALL/CR2 N 56 F Neg B 39 M Neg O A 3, 32 A 3 PBSC 16.2 9.0 2.2
1607 Secondary
AML/CR2
N 52 F Pos B 24 M Neg O — — BM 3.1 3.3 ND
1574 MDS/RAEB N 55 M Neg O 38 M Neg O — — PBSC 8.4 5.5 ND
1498 CLL/stage IV N 59 M Pos O 38 M Neg B — — PBSC 16.0 2.0 5.0
Hod indicates Hodgkin disease; Myel, myeloma; MDS, myelodysplastic syndrome; CML, chronic myelogenous leukemia; AML, acute myelogenous leukemia; CLL, chronic lymphocytic leukemia;
Ph ALL, Philadelphia chromosome–positive acute lymphoblastic leukemia; CR, complete remission; Rel, relapse; CP, chronic phase; AP, accelerated phase; RA, refractory anemia; RAEB, refractory
anemia with excess blasts; CMV, cytomegalovirus serologic status at transplantation; ABO, red blood cell typing; TNC, total nucleated cell count; PD, progressive disease; NHL, non-Hodgkin
lymphoma; Neg, negative; Pos, positive; BM, bone marrow; PBSC, peripheral-blood stem cells; ND, not done; HSCT, hematopoietic stem cell (HSC) transplantation.
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ATG in Nonmyeloablative Unrelated Donor Transplantation
Besult of the high CSP levels (data not shown). Most
atients also experienced a decrease in renal function.
ne patient (patient 1562) was switched from cyclo-
porine to tacrolimus at 2 weeks after transplantation
ecause of malignant hypertension resulting in sei-
ures. This patient subsequently died of Epstein-Barr
irus–associated high-grade non-Hodgkin lymphoma
f the cerebellum.
nfectious Complications
Fevers of undetermined origin or bacterial infec-
ions occurred during the initial period of neutropenia
or most of the patients who experienced marrow
ypoplasia. One patient (patient 1245) who previously
xperienced failure of a related donor transplantation
or myelodysplastic syndrome developed a fatal mu-
ormycosis infection of the sinus, and 1 patient (pa-
ient 1279) died of Candida tropicalis sepsis on day 15
fter transplantation. CMV reactivation occurred for
patients during the ﬁrst 100 days after transplanta-
ion (Table 3). All patients who experienced CMV
eactivation were treated with ganciclovir, and no pa-
ient developed CMV disease. Two cases of respira-
ory syncytial virus infection occurred, and 1 of these
rogressed to lower respiratory tract pneumonia with
fatal outcome despite ribavirin inhalational therapy.
raft-versus-Host Disease
No patient in this study died from uncontrolled
cute or chronic GVHD. Only 6 patients required treat-
able 2. Chimerism Studies
Time n CD3 CD33
28 d 14 92.5 (1-100) 98 (1-100)
56 d 17 95 (0-100) 100 (2-100)
84 d 13 99 (60-100) 100 (86-100)
6 mo 10 100 (85-100) 100 (65-100)
12 mo 9 100 (75-100) 100 (51-100)
hown are the median percentage CD3 or CD33 cells (range) of
donor origin from peripheral blood samples obtained at the
indicated time after transplantation.
able 3. CMV Reactivation Through Day 100
Event
No.
Reactivated/
No. in Group*
ay 100 CMV reactivation
Pretransplantation serology (patient/donor)
Pos/pos 1/5
Pos/neg 7/9
Neg/pos 0/2
Neg/neg 1/7
Number of patients who had evidence of CMV reactivation by antigen
testing during the ﬁrst 100 days after transplantation. These data are
shown according to patient and donor serologic testing before trans-oplantation. Pos indicates positive; Neg, negative.
B&MTent for grade II acute GVHD of the skin (n 3), skin
nd stomach (n  2), or stomach alone (n  1). A
eventh patient developed grade IV acute GVHD of the
iver. An additional 5 patients developed limited (grade I)
cute GVHD of the skin, which resolved for all patients
espite tapering of MMF and CSA and without requir-
ng speciﬁc therapy (Figure 1; Table 4). Acute GVHD
ccurred early, usually before the taper of MMF was
nitiated, and was easily managed with initiation of cor-
icosteroids. No patient required a delay in initiation of
he MMF taper because of acute GVHD. Limited or
xtensive chronic GVHD requiring treatment occurred
or 9 of 13 patients who survived more than 100 days
fter transplantation (Figure 2; Table 4).
elapse
Relapse or disease progression occurred for 7 pa-
ients and was the primary cause of death for 6 (Table 4).
isease progression occurred early after transplantation,
efore a graft-versus-disease immunologic effect is ex-
ected to occur. Both patients with chronic myeloge-
ous leukemia were treated with imatinib, and 1 patient
patient 1562) subsequently achieved a complete remis-
ion without evidence of leukemia by cytogenetic or
olecular testing. A patient with chronic lymphocytic
eukemia (patient 1378) with a progressive increase in
he size of his adenopathy early after transplantation
esponded to the scheduled taper of immunosuppression
nd subsequent DLI and achieved a durable partial re-
ission; progressive disease was again documented at 20
onths after transplantation.
utcome
Seven patients remain alive and without evidence of
isease at a median of 469 days (range, 328-839 days)
fter transplantation (Table 4). The actuarial probability
igure 1. The probability of developing grade II to IV acute
VHD before day 100 after transplantation. Tic marks represent
atients without acute GVHD.f event-free survival at 1 year after transplantation for
789
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7his mixed population of patients is 38% at 1 year after
ransplantation (Figure 3).
ISCUSSION
Donor cell engraftment is achieved by using any of
number of reduced-intensity conditioning regimens
4]. Most regimens include a purine analog such as
udarabine with a variety of other agents. The regi-
able 4. Chimerism, GVHD, and Transplantation Outcomes
Patient
No.
% Donor CD3 Cells
GVHD
Day 28 Day 56 Day 84
Acute
(Day Onset) (
1192 ND 90 100 0 S,
859 100 100 100 I S (50) S,
1279 NE NE NE 0 NE
1272 1 0 NE 0 NE
1272 80 100 100 0 0
818 100 98 NE 0 NE
1159 ND 97 NE II G (67) 0
1356 NE NE NE 0 NE
1378 95 100 100 0 S,
1397 100 87 NE II S, G (21) NE
1406 90 100 98 0 S,
1418 100 100 100 IV L (4) S (
1455 60 65 NE 0 NE
1245 92 95 NE II S, G (44) NE
1476 ND 100 99 I S (27) S,
1477 75 NE NE 0 NE
1508 100 100 90 0 0
1540 75 80 75 I S (60) S,
1562 80 60 60 I S (40) S,
1582 99 100 100 II S (41) 0
1607 62 86 84 I S (47) S,
1574 36 NE NE II S (15) NE
1498 ND 80 95 II S (21) NE
LI indicates donor lymphocyte infusion; S, skin; G, gut; M, mo
CCR, continuous complete remission; MRSA, methicillin-resista
failure; EBV-PTLD, Epstein-Barr virus posttransplantation lym
igure 2. The probability of developing chronic GVHD requiring
reatment after transplantation. Tic marks represent patients with-
ut chronic GVHD. s
90en used in this study is based on the observation in
canine transplantation model that small doses of TBI
re adequate to achieve engraftment of donor hema-
opoietic cells when used in conjunction with a potent
osttransplantation immunosuppressive regimen [3].
n human trials, ﬂudarabine was subsequently added
o the low-dose TBI conditioning regimen because of
he high (20%) rate of failure of durable engraftment
DLI
Event Time
Status
(or Cause of Death)
nic
nset)
Relapse
(d)
Survival
(d)
6) Y 265 663 Progressive disease
7) Y 284 392 Adenovirus hepatitis
N — 15 Candida tropicalis
pneumonia
N — — FTE
N — >839 CCR
N 56 95 Progressive disease
N 40 138 Progressive disease
N — 19 Enterococcus sepsis
9) Y 66 664 Progressive disease
N — 97 MRSA sepsis
166) N — >700 CCR
N — >673 CCR
N 39 56 Progressive disease
N — 71 Mucor sinusitis
8) N — >533 CCR
N — 50 Cardiac tamponade
N — >474 CCR
1) N — >438 CCR
7) N 21 156 EBV-PTLD
N 57 138 Progressive disease
) N — >328 CCR
N — 47 RSV pneumonia
N — 83 MOF
liver; 0, no GVHD; NE, nonevaluable; FTE, failure to engraft;
hylococcus aureus; RSV, respiratory syncytial virus; MOF, multiorgan
oliferative disease; ND, not done.
igure 3. The probability of event-free survival after transplanta-
ion. Patients were censored at the time of relapse or death. Tic
arks represent patients alive and in continuous complete remis-Chro
Day O
G (27
M (11
M (12
M, L (
169)
G (25
M (32
G (12
G (97
uth; L,
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ATG in Nonmyeloablative Unrelated Donor Transplantation
Bor recipients of cells from related donors who were
onditioned with TBI alone [5]. Although the addition
f ﬂudarabine improved the probability of successful
himerism for related-donor transplantation, condi-
ioning with this combination of ﬂudarabine and TBI
till resulted in failure of sustained engraftment for
5% to 45% of patients who received cells from un-
elated donors [6,7].
Our data show that the addition of rATG to this
egimen of ﬂudarabine and single-fraction TBI moder-
ted both the host-versus-graft and graft-versus-host re-
ctions, thereby decreasing the risks of engraftment fail-
re and acute GVHD. Rabbit-derived ATG, like the
osttransplantation administration of cyclosporin A and
MF, suppresses both host and donor immune reactiv-
ty even if given before transplantation, as a result of its
alf-life of 6 days, with resulting persistence in the cir-
ulation for many days [14,15]. The actuarial probability
f developing acute GVHD grade II to IV before day
00 was 40%; only 1 of 17 evaluable patients did not
chieve donor cell chimerism at day 56 after transplan-
ation. The patient enrollment criteria and the trans-
lantation regimen used in this study were otherwise
dentical to previously reported studies that did not in-
lude rATG [6,7], and successful engraftment was
chieved for recipients of either marrow or PBSC prod-
cts regardless of diagnosis. Nine of 14 patients not
reated with DLI and who were alive more than 3
onths after transplantation developed chronic GVHD
equiring treatment, and this suggests that the addition
f rATG to the conditioning regimen did not protect
gainst this complication of unrelated donor HSC trans-
lantation. However, neither acute nor chronic GVHD
as a cause of death for any of the patients in this series.
hese results support our hypothesis that the additional
mmunosuppression gained by the use of this reagent
ould be effective in decreasing both the host-versus-
raft and graft-versus-host events observed in the pre-
eding studies of unrelated donor transplantation with
udarabine and TBI conditioning.
The mechanism of immunosuppression achieved
y the infusion of ATGs is, presumably, a result of cell
epletion both in the blood and in the secondary
ymphoid organs, although it is not known which cells
re the primary targets of these polyclonal antibody
ocktails [16,17]. Rabbit-derived ATG is isolated from
he pooled sera of large numbers of rabbits inoculated
ith human thymocytes. In contrast to equine ATG,
ATG consists of a single immunoglobulin G isotype,
as higher afﬁnity for the human Fc receptor, and is
ore potent in T-cell depletion in humans [18]. Rab-
it-derived ATG is a polyclonal product with multiple
ntibodies targeted to a broad range of lymphocyte
ntigens, including CD2, CD3, CD5, CD45, and T-
ell receptor, and infusion of rATG results in a rapid
nd persistent depletion of peripheral blood lympho-
ytes. The addition of ATGs to the transplantation a
B&MTonditioning regimen reduces the risk of graft rejec-
ion in murine models and human transplantation
19-21].
A number of transplant programs have reported
linical studies of related or unrelated donor trans-
lantation with the addition of rATG to a dose-in-
ense conditioning regimen [9,10,22-25]. Several of
hese studies described risks of grade II to IV acute
VHD of only 20% to 40% with regimens that in-
luded rATG in dosages ranging between 2.5 and
5 mg/kg. Bacigalupo et al. [9] described a higher
ncidence of infectious complications for patients
reated with the higher doses of rATG but also de-
cribed a lower risk of chronic GVHD [10]. Finke et
l. treated 100 adult patients undergoing matched or
ismatched unrelated donor transplantation with a
ifferent preparation of rabbit anti–T-lymphocyte
lobulin as part of the conditioning regimen and used
yclosporine and short-course methotrexate for
VHD prophylaxis [26]. The cumulative incidences
f grade II to IV acute GVHD for this consecutively
reated cohort of patients were only 21% for recipi-
nts of matched and 20% for recipients of mismatched
rafts. The great majority of the patients in these
tudies involving ATG received bone marrow as a
ource of HSC, which might explain the lower inci-
ences of chronic GVHD than found for our study
27-31]. In a study with a design similar to the study
eported here, involving conditioning with ﬂudara-
ine 90 mg/kg and 200 cGy of TBI but with the
ddition of equine ATG, donor cell engraftment was
chieved for more than 90% of evaluable patients, and
nly 1 patient in that series of 25 patients receiving
ells from related or unrelated donors rejected the
onor cells [32]. However, 4 patients succumbed to
omplications of GVHD, and the authors concluded
hat the addition of equine ATG did not reduce the
isk of severe GVHD. Although randomized studies
omparing the 2 rabbit globulins in heart transplan-
ations showed no difference in rejection episodes and
ong-term survival [33], a difference was found in a
andomized study comparing equine ATG with rATG
18,34], and it is likely that the spectrum of activity
aries between different ATG preparations [35].
Study design and the small number of patients
nrolled limits our ability to deﬁne precise estimates
f risk for such complications of transplantation as
pportunistic infections or posttransplantation relapse
hat may have been increased as a result of the addi-
ional immunosuppression achieved. Recovery of im-
unologic function was not an end point of this trial.
nfections were a primary cause of death (Table 4),
ccurring for 5 of 23 transplantations, although no 1
lass of pathogen predominated. The incidence of
MV reaction, an indicator of the degree of immu-
osuppression, did not seem higher than expected,
nd no patient developed CMV disease. One patient
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7eveloped Epstein-Barr virus–associated posttrans-
lantation lymphoproliferative disorder, a possible
omplication of the increased immunosuppression
chieved with rATG administration [36]. The low-
ose conditioning regimen of ﬂudarabine and TBI
chieves minimal control of malignancy, and disease
rogression occurred early for several patients en-
olled on this study. Relapses occurred for patients
ith more advanced diseases, such a multiple my-
loma progressing on other therapies, and there is no
vidence that the addition of rATG to the condition-
ng regimen increased the likelihood of posttransplan-
ation relapse through suppression of the alloimmune
raft-versus-disease effect. Selection of a more cyto-
oxic conditioning regimen may be necessary for
reatment of patients with advanced malignancies,
uch as multiple myeloma that failed a prior autolo-
ous transplantation, to allow time for a graft-versus-
isease effect to develop. For example, none of our
atients treated for myelodysplasia or acute myeloge-
ous leukemia in remission relapsed, and these data
ncourage further exploration of nonmyeloablative
onditioning regimens in the treatment of these dis-
ases. Similar observations about the efﬁcacy of trans-
lantation for these diseases have been published by
ther transplant teams [36,37].
In comparison to the reports of unrelated donor
ransplantation with ﬂudarabine and TBI condition-
ng without rATG [6,7], this series of patients seems
o have experienced lower rates of engraftment failure
nd severe acute GVHD while achieving similar sur-
ivals. An appropriately controlled, randomized trial
ould be necessary to conﬁrm the advantages and
isadvantages of adding rATG to the ﬂudarabine and
BI regimen, and future trial designs should include
easurement of immunologic recovery to help delin-
ate the effects of the additional immunosuppression
n long-term immune system function. However, the
bility to achieve reliable engraftment of donor cells is
n important consideration, in particular for unrelated
onor transplantation, for which there may be difﬁ-
ulty in obtaining cells for salvage of engraftment
ailure and for which the transplant center has less
ontrol over the quantity of cells obtained. This reg-
men is appropriate for efﬁcacy studies in patients with
ess aggressive hematologic diseases, such as myelo-
ysplasia and chronic leukemias, and it may also serve
s a platform for establishing host cell chimerism for
hase I studies of other forms of active immunother-
py with allogeneic cells.
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